These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39182090)

  • 1. Economic implications of step-down outpatient management for fever and neutropenia episodes in pediatric cancer patients: a cost minimization analysis.
    Avilés-Robles MJ; Reyes-López A
    BMC Health Serv Res; 2024 Aug; 24(1):981. PubMed ID: 39182090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
    Cosler LE; Sivasubramaniam V; Agboola O; Crawford J; Dale D; Lyman GH
    Value Health; 2005; 8(1):47-52. PubMed ID: 15841893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of outpatient management for febrile neutropenia in children with cancer.
    Teuffel O; Amir E; Alibhai SM; Beyene J; Sung L
    Pediatrics; 2011 Feb; 127(2):e279-86. PubMed ID: 21220399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of step-down to oral outpatient treatment versus inpatient antimicrobial treatment in pediatric cancer patients with febrile neutropenia: A noninferiority multicenter randomized clinical trial.
    Avilés-Robles MJ; Reyes-López A; Otero-Mendoza FJ; Valencia-Garin AU; Peñaloza-González JG; Rosales-Uribe RE; Muñoz-Hernández O; Garduño-Espinosa J; Juárez-Villegas L; Zapata-Tarrés M
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28251. PubMed ID: 32196898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic comparison of home-care-based versus hospital-based treatment of chemotherapy-induced febrile neutropenia in children.
    Raisch DW; Holdsworth MT; Winter SS; Hutter JJ; Graham ML
    Value Health; 2003; 6(2):158-66. PubMed ID: 12641866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients.
    Teuffel O; Amir E; Alibhai S; Beyene J; Sung L
    Br J Cancer; 2011 Apr; 104(9):1377-83. PubMed ID: 21468048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National cost savings from an ambulatory program for low-risk febrile neutropenia patients in Australia.
    Tew M; Forster D; Teh BW; Dalziel K
    Aust Health Rev; 2019 Oct; 43(5):549-555. PubMed ID: 31526466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs associated with febrile neutropenia in the US.
    Michels SL; Barron RL; Reynolds MW; Smoyer Tomic K; Yu J; Lyman GH
    Pharmacoeconomics; 2012 Sep; 30(9):809-23. PubMed ID: 22804805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study.
    Brack E; Bodmer N; Simon A; Leibundgut K; Kühne T; Niggli FK; Ammann RA
    Pediatr Blood Cancer; 2012 Sep; 59(3):423-30. PubMed ID: 22271702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analysis of the resource use and costs of febrile neutropenia events in pediatric cancer patients in Australia.
    Vargas C; Haeusler GM; Slavin MA; Babl FE; Mechinaud F; Phillips R; Thursky K; Lourenco RA;
    Pediatr Blood Cancer; 2023 Nov; 70(11):e30633. PubMed ID: 37592047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection.
    Santolaya ME; Alvarez AM; Avilés CL; Becker A; Cofré J; Cumsille MA; O'Ryan ML; Payá E; Salgado C; Silva P; Tordecilla J; Varas M; Villarroel M; Viviani T; Zubieta M
    J Clin Oncol; 2004 Sep; 22(18):3784-9. PubMed ID: 15365075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness and Improved Parent and Provider Satisfaction With Outpatient Management of Pediatric Oncology Patients, With Low-risk Fever and Neutropenia.
    Bavle A; Grimes A; Zhao S; Zinn D; Jackson A; Patel B; Porea T; Dutta A; Russell H; Heczey A
    J Pediatr Hematol Oncol; 2018 Oct; 40(7):e415-e420. PubMed ID: 29334532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Febrile Neutropenias in Adolescents and Young Adults: A Cost-Minimization Analysis Between Adult Versus Pediatric Units.
    Penel-Page M; Marec-Bérard P; Morelle M; Bertrand A; Riberon C; Boyle H; Perrier L
    J Adolesc Young Adult Oncol; 2017 Dec; 6(4):542-550. PubMed ID: 28678005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outpatient therapy for febrile neutropenia: clinical and economic implications.
    de Lalla F
    Pharmacoeconomics; 2003; 21(6):397-413. PubMed ID: 12678567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of a clinical pathway for primary outpatient management of pediatric patients with low-risk febrile neutropenia.
    Paolino J; Mariani J; Lucas A; Rupon J; Weinstein H; Abrams A; Friedmann A
    Pediatr Blood Cancer; 2019 Jul; 66(7):e27679. PubMed ID: 30916887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomised trial.
    Orme LM; Babl FE; Barnes C; Barnett P; Donath S; Ashley DM
    Pediatr Blood Cancer; 2014 Aug; 61(8):1427-33. PubMed ID: 24604835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in management of low-risk febrile neutropenia.
    Teuffel O; Sung L
    Curr Opin Pediatr; 2012 Feb; 24(1):40-5. PubMed ID: 22037219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma.
    Li S; Liu J; Bowers C; Garawin TAFS; Kim C; Bensink ME; Chandler DB
    Support Care Cancer; 2020 Jan; 28(1):113-122. PubMed ID: 30993450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of direct medical costs of hospitalization for febrile neutropenia.
    Lathia N; Mittmann N; DeAngelis C; Knowles S; Cheung M; Piliotis E; Shear N; Walker S
    Cancer; 2010 Feb; 116(3):742-8. PubMed ID: 20029970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs associated with febrile neutropenia in solid tumor and lymphoma patients - an observational study in Singapore.
    Wang XJ; Wong M; Hsu LY; Chan A
    BMC Health Serv Res; 2014 Sep; 14():434. PubMed ID: 25252614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.